Introduction {#s1}
============

Worldwide around 382 million people have been diagnosed with type 2 diabetes mellitus. With an increasing incidence of type 2 diabetes, this disease has engrossed great concern (Du et al., [@B14]). It is characterized by high level of blood glucose resulting from synergistic effect of reduced insulin production and insulin resistance by the pancreatic β-cell (Lizarzaburu et al., [@B56]). One of the important features is the deterioration of glucose control progressively over a period of time. The hyperglycemia increases the risk of cardiovascular complications in patients with diabetes that includes stroke, neuropathy, nephropathy, and retinopathy. Hence, to prevent chronic diabetic complications, it is important to have effective glycemic control (Ahrén, [@B1]). Presently, sulfonylureas and meglitinide as insulin secretagogues are being used for treatment of type 2 diabetes in patients (Winzell and Ahrén, [@B72]). However, these compounds lead to insulin release independent of blood sugar level and result into hypoglycemia. The novel glucose stimulated insulin secretagogues such as 5 GLP-1 analogs, DPP-IV inhibitors, GPR119 agonists and GPR40 agonists have opened new and alternative treatment against Type 2 diabetes (Augeri et al., [@B2]). Also, diabetes requires multi-drug therapies with a new intervention every few years to have better control. Hence, it is essential to develop the therapies that can lower the glucose level in the blood without risk of hypoglycemia.

GPR142, an orphan G protein-coupled receptor, is predominantly expressed in pancreatic β-cells (Overton et al., [@B61]). The stimulation of GPR142 by tryptophan initiated intracellular signal transduction leads to enhanced glucose dependent insulin secretion in isolated mouse islets (Kahn et al., [@B39]). Hence, GPR142 can be a potentially advantageous drug target for diabetes therapy and can provide an alternative therapy with reduced risk of hypoglycemia. However, the 3D-structure and signaling pathways downstream of GPR142, and its mechanisms are poorly characterized.

In this study, we have reported the structure based virtual screening to find the hit compounds that can be used to develop potential leads for novel agonists of GPR142 (Gund et al., [@B23]; Hopfinger, [@B33]; Guner, [@B24]). The compounds were validated through induced fit docking studies whilst ligand based virtual screening was employed for pharmacophore modeling to derive the structural requirements crucial for receptor binding (Dixon et al., [@B13]). A complete network pathway was constructed, and kinetic studies were carried out for the screened compounds binding to GPR142 to better understand the mechanism as well as effect on insulin secretion.

Methodology {#s2}
===========

3D structure prediction and validation
--------------------------------------

The sequence of GPR142 (UniProt ID: [Q7Z601](Q7Z601) and GenBank ID: [NP-861455.1](NP-861455.1)) was retrieved from UniProt Database (Chen et al., [@B10]; Pundir et al., [@B63]). As there is no solved crystal structure of GPR142 and sequence showed a homology of only 21%, 3D structure prediction was done using threading and *de-novo* methods. The threading approach was based on sequence-structure alignment that includes searching of homologous protein structures in the PDB (Lemer et al., [@B55]). Whereas, ab initio modeling was based on conformational search under the guidance of a designed energy function and model precision was highly defined by the protein sequence length i.e., \<100 amino acid residues produced better results (Hardin et al., [@B29]). A Delta-type opioid receptor chimeric protein \[PDB ID: 4N6H\] (Fenalti et al., [@B17]) was initially selected as reference template for build secondary structure of GPR142 using Modeler v9.8 program (B. Webb, A. Sali. 2014, Eswar et al., [@B15]). The 3D modeled structure of GPR142 was then prepared using Protein Preparation Wizard (Sastry et al., [@B64]). The model was further validated by various modules available in SAVE server (Lüthy et al., [@B57]; Colovos and Yeates, [@B11]; Laskowski et al., [@B54]; Hooft et al., [@B32]; Pontius et al., [@B62]; Vaguine et al., [@B70]; Benkert et al., [@B8], [@B6],[@B7], [@B5]). The methodology adapted in this manuscript is shown as flowchart in Figure [1](#F1){ref-type="fig"}.

![Flow chart diagram for the modeling, Virtual screening, Pharmacophore generation, and 3D database screening for potential lead compounds as GPR142 agonists.](fchem-06-00023-g0001){#F1}

3D tunnel and domain prediction
-------------------------------

To understand the mechanism of ligand movement and probable binding sites, tunnels were located in the modeled structure of GPR142 using CAVER2.1 (Beneš, [@B3]; Beneš et al., [@B4]). Domain predictions were performed using TMbase (Hofmann and Stoffel, [@B31]) and GPCRHMM server (Wistrand et al., [@B73]). TMbase and GPRCRHMM algorithm were based on statistical and HMM analysis, respectively.

Active site prediction
----------------------

Sitemap module of Schrödinger software suite (Halgren, [@B26], [@B27]) was used to predict the binding site of GPR142. SiteMap used the interaction energies to locate the energetically favorable regions. It initially traced the sites that include a set of site points on a grid. The numbers of site points for a site were set to 15 and the number of sites to be found was set to 5. More restrictive definition of hydrophobicity and OPLS force field was used for all the calculations.

Receptor based virtual screening
--------------------------------

The structure based virtual screening analysis was performed using Virtual screening workflow of Schrödinger software suite (Friesner et al., [@B18], [@B19]; Halgren et al., [@B28]) against different libraries of compounds. All the ligand structures present in the databases were in 2D SDF format and converted to 3D for docking studies. OPLS 2005 force field (Jorgensen and Tirado-Rives, [@B38]; Jorgensen et al., [@B37]; Shivakumar et al., [@B69]) was used for geometry optimization by truncated newton conjugate gradient (TNCG) minimization. Receptor grid was generated using centroid of active site residues with van der Waals scaling factor of 1.0 and partial charge cutoff at 0.25. LigPrep (Schrödinger Release, [@B65]) was used to prepare the ligands with Epik (Shelley et al., [@B66]; Greenwood et al., [@B21]) at 7 ± 2.0 pH units to expand protonation and tautomeric states with OPLS2005 force field. Low energy stereoisomers were generated for each ligand and ones holding low energy 3D structures with correct chiralities were retained. The different used libraries were namely; (1) Zinc, (2) SchrodingerDB, (3) TimTec, (4) PUBCHEM, (5) Not annotated NCI, (6) Marine, (7) DrugBank (Approved, Biotech, ILLICIT, Investigational, Nutraceutical, Withdrawn), (8) ChemBank, (9) Anti-HIV NCI, (10) DrugLikness NCI, (11) Asinex Ltd., and (12) ChEBI (Grotthuss et al., [@B22]; Irwin and Shoichet, [@B34]). Virtual screening was carried out in three phases: (a) Structure based virtual screening (HTVS), (b) Standard Precision (SP), and (c) (XP); Top 20 screened compounds were selected following virtual screening based on docking score range (−13.041 to −8.0).

Validation
----------

The top 20 compounds screened through virtual screening were validated through blind docking, induced fit docking, and pharmacophore generation. The validated compounds were then used for further studies.

### Blind docking

Blind Docking using SP and XP was done without specifying the active site residues. The epik state penalties were added to the docking score (Shelley et al., [@B66]; Greenwood et al., [@B21]). Scaling of van der Waals radii was also set to 0.8 and partial charge cutoff at 0.15. The number of poses generated per ligand was 100.

### Induced fit docking

The 20 screened compounds were evaluated by induced fit docking (IFD) (Farid et al., [@B16]; Sherman et al., [@B67],[@B68]) wherein flexibility was imparted to the residues in active site and its vicinity in GPR142, and implicit membrane was used in induced fit docking. All the ligands were prepared using LigPrep (Schrödinger Release, [@B65]) and were optimized with OPLS force field. The induced fit docking was carried out in different stages. During first stage, ligands were docked to rigid protein using initial softened-potential Glide docking with vdW van der Waals radii scaling of 0.7/0.5 for receptor/ligand, respectively. The top 20 poses for each test ligand were used to sample protein plasticity using Prime module of Schrodinger suite software (Jacobson et al., [@B35], [@B36]). In the next step, receptor sampling and refinement was performed. Residues having at least one atom within 5 Å of any of the 20 ligand poses were subjected to a conformational search and minimization while residues outside this range were fixed. So, in this way the flexibility of proteins was taken into account. The backbone, side-chains and ligand were subjected to subsequent energy minimizations. Further, re-docking of the ligands was carried out into their respective 10 structures that were selected within 30.0 kcal/mol of their lowest energy structure. Glide XP (extra precision) was used for all the docking calculations. Finally, ligand poses were scored using a combination of Glide Score functions and Prime (Jacobson et al., [@B35], [@B36]) where the top ranked poses for each ligand were chosen as their respective final results.

### Pharmacophore development

The common pharmacophore hypothesis was performed using Phase module of Schrödinger software suite (Dixon et al., [@B12]). Sixty compounds had been reported as potential GPR142 agonists (Du et al., [@B14]; Lizarzaburu et al., [@B56]) and compounds with EC~50~ value range between 0.036 and 33.00, were selected from literature. These compounds were prepared by generation of stereoisomers, neutralizing the charges on the structures and generating ionization states at pH 7.0 using OPLS2005 force fields. One thousand conformers were generated per compound by ConfGen module of Schrodinger suite software (Watts et al., [@B71]). All the conformations were pre-minimized and post-minimized. OPLS2005 force field was used with GB/SA water solvent treatment for calculation of minimization. Distance dependent dielectric and maximum relative energy difference were 10.0 Kcal/mol relative to the global energy minima and redundant conformers were eliminated.

The Pharmacophore features i.e., Acceptor (A), Donor (D), Hydrophobic (H), Negative (N), Positive (P), and Aromatic Rings (R) defined by three chemical structure patterns were point, vector and groups as SMARTS queries. These patterns were assigned as one of three possible geometries, which defined the physical characteristics of site. In case of aromatic rings, the site includes directionality, defined by a vector that is normal to plane of the ring.

A scoring function was used to examine the common pharmacophore features (CPHs) to yield the best alignment of active ligands and quality of alignment measured by a survival score defined as:
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where weights are represented by W~Ds~ and scores are represented by S~Ds~, and S~site~ represents an alignment score, S~vec~ represents the vector score and averages the cosine of the angles formed by corresponding pairs of vector features in aligned structures. S~vol~ represents the volume score based on overlap of the van der waals models of non-hydrogen atoms in each pair of structures. S~sel~ represents the selectivity score, and accounts for the fractions of molecules that are likely to match the hypothesis regardless of their activity toward a receptor. W~site~, W~vec~, W~vol~, and W~rew~ have a default value of 1.0 while W~sel~ has a default value of 0.0. $\text{W}_{\text{rew}}^{\text{m}}$ represents the reward weights, where m is the number of actives that match the hypothesis minus one.

Different data sets were used to build the pharmacophore features:

#### First data set (high affinity EC~50~ value)

All the 60 compounds were chosen. The activity threshold was set to 0.036. The compounds were considered active above 0.036 and inactive below 0.001. The maximum activity was at 0.930 and minimum activity was 0.036. The hypothesis was selected to match at least 35 compounds out of 38 actives.

#### Second data set (medium affinity EC~50~ value)

All the 60 compounds were in second Dataset and activity thresholds were set in such a way that, the compounds are active if activity was above 1.060 and inactive it was below 1.000. The maximum activity was set at 6.600 and minimum activity was fixed at 1.060. The hypothesis was set to match at least 30 compounds out of 51 actives or active group.

#### Third data set (low affinity EC~50~ value)

All the 60 compounds were chosen in the third Dataset and activity thresholds were set again in such a way that compounds are active if activity was above 0.036 and inactive if below 0.035. The maximum activity was at 33.000 and minimum activity at 0.036. The hypothesis was set to match at least 20 compounds out of 60 actives or active group.

The hypothesis generated was used for matching against screened ligands.

Combining the ligand based virtual screening with structure based virtual screened compounds
--------------------------------------------------------------------------------------------

A Phase database was created for the best compounds obtained from virtual screening from different compound libraries. A maximum of 100 conformers per structure of the phase database were generated and up to 10 conformations per rotable bonds were retained. This database was then searched to match the pharmacophore hypothesis ADPRR. The Phase database was searched for geometric arrangements of pharmacophore sites that match inter-site distances and the site types. The conformers that aligned to the hypothesis were rapidly retrieved from the database. Fitness score was used to filter the conformers or hits and then filtered by number. A comparative analysis was done for experimental compound (with known EC~50~ value 0.036) with compound21 obtained from matching with pharmacophoric hypothesis.

Biochemical pathway construction of GPR142 complexes with the potential compound
--------------------------------------------------------------------------------

In order to explore the signal transduction in cellular process of GPR142 membrane protein that terminates with the regulation of transcription or downstream cellular process and ultimately to understand their effect on insulin secretion, a biochemical pathway for the GPR142 was constructed in presence of potential compound. The interacting species (gene, protein, and other molecules) were prioritized, collected from different sources and literature survey, that included association studies of GPR142 with drug or drug like compounds, linkage studies of GPR142 and GPR41, gene expression studies related to insulin production, drug kinetics in diabetes, and biological regulatory pathways of type 2 diabetes. The concentrations were assigned for each gene, protein and other molecules in micro molar. A mathematical computational model of the signaling pathway of GPR142 was then developed and visualized in Cell Designer v4.4 (Funahashi et al., [@B20]). Systems biology approach was used to investigate interactions of ligands with known EC~50~ vlaues (0.054) and different concentrations of virtual screened ligands against the GPR142. GPR142, GPR41, Gαs, Gαi, Gαq/11, and Gα12/13 data were retrieved from different databases, servers, tools and literature (Kanehisa, [@B40], [@B41], [@B42]; Kanehisa and Goto, [@B44]; Kanehisa et al., [@B47], [@B48], [@B46], [@B43], [@B45], [@B49], [@B50]; Moriya et al., [@B58]; Harmar et al., [@B30]; Kotera et al., [@B53]; Muto et al., [@B59]; Nakaya et al., [@B60]). A complete GPR142 pathway beginning with potential compound binding to GPR142 for Type 2 diabetes was constructed within cell compartment. During simulation the input values were assigned using kinetic irreversible simple Michaelis Menten equatio$n\ V = \frac{VmS}{Km} + S$ and mass action kinetics equation *V* = *K Π*i S. The kinetic simulations were used to investigate which genes and proteins interact with each other and effect the insulin secretion.

Molecular dynamics simulation
-----------------------------

Molecular dynamics (MD) simulation was performed using Desmond package v31023 (Bowers et al., [@B9]; Guo et al., [@B25]; Shivakumar et al., [@B69]). MD simulation of GPR142 complex structure with compound2 and compound21 was performed by Desmond Schrödinger package for 50 ns (nanoseconds) each. The system was build using simple point charge water (SPC) model with membrane model 1-hexadecanoyl-2--(9Z-octadecenoyl)-*sn*-glycero-3-phosphocholine (POPC) by applying periodic boundary conditions (PBC) in simulation box (orthorhombic). An embedded system neutralized with counter ions and geometry of SPC molecules, SHAKE algorithm neutralizing heavy atom bond lengths with hydrogen\'s and particle mesh ewald (PME) were applied for electrostatic interactions. The full system composed of GPR142 structure with compound2 and compound21 was simulated through multistep MD simulation protocols, where initially system was minimized with restraints on solute for maximum 2,000 iterations using steepest descent and followed by conjugate gradient algorithm with 50.0 kcal/mol/Å threshold energy. The system equilibrations were performed by applying 10 ps (picoseconds) simulation time for non-hydrogen solute atoms in NVT ensemble at 10 K temperature. Then 12 ps MD simulations were performed for restraining non-hydrogen\'s solute atoms in the NPT ensemble at 10 K temperature. Further, 24 ps MD simulation were performed for restraining all non-hydrogen solute atoms in the NPT ensemble at 300 K temperature and similarly 24 ps MD simulation were again performed to relax the system without restraints in the NPT ensemble at 300 K temperature. Complex structure of GPR142 with compound2 and compound21, 50 ns each MD simulations were performed. Trajectories were recorded after every 4.8 ps, where energy recording interval was 1.2 ps. RMSD and RMSF of the complex structure of GPR142 with compound2 and compound21 in each trajectory was analyzed with respect to 50 ns simulation using OPLS2005 (Optimized Kanhesia for Liquid Simulations) force fields.

Results {#s3}
=======

Structural modeling and validation of 3D-model of GPR142
--------------------------------------------------------

The 3D-structure of GPR142 was modeled using threading and *ab initio* method. Ab initio approach is based on the "thermodynamic hypothesis," which states that the native structure of a protein is the one for which the free energy achieves the global minimum; ab initio is most difficult approach, but a very useful approach. Threading and ab initio/*de-novo* approach were applied to predict the 3D structure of GPR142 using available structural information from the resolved X-Ray structures in PDB databank. Out of 462 amino acids, 283 were modeled from residue 151-433. Residues 1-150 from the N-terminus and 434-462 from the C-terminus were trimmed (Kaushik and Sahi, [@B52]). A total of twenty models were generated and validated by SAVE server (Kaushik and Sahi, [@B52]). Best predicted model structures were further refined by using Modeler v9.8, calculation of probability density function (pdfs) and Discrete optimized potential energy (DOPE). The 3D-model had DOPE score of −34453.63 which was lowest against the predicted other models. Also, Ramachandran plot showed 94.9% residues in the allowed region that depicted the stability of predicted model.

Active site prediction
----------------------

The top ranked potential receptor binding sites were identified using SiteMap. The best site had a score of 1.12 Å, 521 Å^3^ volume, 0.72 hydrogen bond acceptor score, 0.68 hydrophilic score, and 1.00 hydrophobic score. The active site residues were identified as Phe212, Arg224, Asn235, Glu238, Trp300, Arg301, Lys314, and Asp397. Active site regions were largely located in extracellular regions of seven transmembrane domains where the potential leads can bind and play crucial role in signal transduction.

3D tunnel representation and domain prediction
----------------------------------------------

Figure [2](#F2){ref-type="fig"} represents the Trans membrane domains: 160 to 182, TM2 194 to 216, TM3 236 to 258, TM4 278 to 300, TM5 315 to 337, TM6 357 to 379, and TM7 394 to 416. The tunnels were generated using CAVER2.1 program. The tunnel leading to active site had following coordinates; X coordinate at −4.95, Y coordinate at −70.93, and Z coordinate at 66.58. Whereas, bottleneck radius, length, curvature average gate radius was 3.60, 12.01, 1.03, and 4.67, respectively.

![**(A)** Predicted active site of GPR142 using Sitemap showing different domains. (**B)** Tunnel region of GPR142; where active site resides (Surface in mesh form) are color coded according to their property like hydrophobicity, charge, and polarity. The Orange color depicts GLY and atoms without PDB residues name, Green, Hydrophobic residues; Cyan, Polar uncharged residues; Blue, Positively charged residues, and Red, Negatively charged residues.](fchem-06-00023-g0002){#F2}

Receptor based virtual screening
--------------------------------

A total of 1171519 compounds obtained from different libraries were docked into the predicted active site of GPR142. A step wise filtering protocol was used, in the first stage compounds were docked using HTVS where a total of 112,927 hits were obtained. These 112,927 compounds were further docked with Glide SP where a total of 11,281 hits were obtained. Finally, the hits from previous stage were subjected to Glide XP docking and only one pose per ligand was retained. Finally, a total of 1,120 hits were obtained as shown in Table [1](#T1){ref-type="table"}.

###### 

Combinatorial library of chemical compounds which represents the number of input compounds in different parameters of Glide Schrodinger suite software and number of outputs compounds.

  **Zinc**            **358399**   **35831**   **3576**   **349**   **349**
  ------------------- ------------ ----------- ---------- --------- ---------
  SchrodingerDB       416151       41615       4161       416       415
  TimTec              9211         921         92         09        09
  PUBCHEM             21592        2159        215        21        20
  Not annotated NCI   17487        1748        174        17        01
  Marine              419          41          04         01        01
  DrugBank            5352         532         52         08        08
  ChemBank            3919         391         39         3         03
  Anti HIV NCI        10100        1010        101        10        10
  Drug Likness NCI    200052       20005       2000       200       200
  Asinex Ltd.         86748        8674        867        86        86
  ChEBI               42089        0           0          0         0
  Total               1171519      112927      11281      1120      1120

*Top 20 screened compounds were shortlisted on the basis of docking scores (range −13.041 to −8.0)*.

Compound1 with a docking score of −13.041 is a comfortable legend in the active site of GPR142. The 2,4-dioxo-(1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl moiety forms hydrogen bond with side chain residues Arg224 and Asp397. The oxy phosphinato moieties form strong H-bond interactions with side chains residues Asn235, Arg301, and Lys314. The amino group of the dihydropyrimidine moiety forms H-bond with the backbone oxygen of residues Phe212 and Arg224 (Figure [3](#F3){ref-type="fig"}). The interactions analysis for the 20 screened compounds is given in the Table [2](#T2){ref-type="table"} and their 2D structures are given in Supplementary Data (Table [S3](#SM1){ref-type="supplementary-material"}).

![Compounds1 docked in the active of GPR142. The compound is shown in sticks and the protein is depicted as ribbons and H-bonding is shown as dotted lines.](fchem-06-00023-g0003){#F3}

###### 

Top 20 screened chemical compounds screened based on using virtual screening along with respective Glide emodel score, number of Glide poses, their hydrogen bond interactions, and ADMET properties.

  **Compound\'s**   **Molecular formula**   **Database\'s**   **Docking score**   **Glide emodel**   **Glide poses**   **Interactions (Hydrogen bond interactions)**                            **logP**   **logS**
  ----------------- ----------------------- ----------------- ------------------- ------------------ ----------------- ------------------------------------------------------------------------ ---------- ----------
  Compound 1        C18H23N5O21P4           DrugBank          −13.041             −93.629            40                Arg301, Asn235, Phe212, Arg224, Asp397, Lys314                           −0.53      −1.34
  Compound 2        C27H30O16               ChemBank          −11.331             −88.517            1                 Arg224, Leu396, Asp397, His393, Asp389                                   0.15       −2.24
  Compound 3        C28H32O15               ChemBank          −11.265             −90.187            5                 Arg301, Asn235, Lys314, Gln225                                           0.08       −2.60
  Compound 4        C19H26I3N3O9            DrugBank          −10.694             −78.884            32                Asp389, His393, Asn400, Arg224, Phe212                                   −2.78      −2.66
  Compound 5        C21H26N7O14P2           ChemBank          −10.433             −93.381            1                 Asp389, His393, Leu222, Arg224, Lys314, Arg301, Ala213, Ala234, Asn235   −1.38      −2.22
  Compound 6        C41H42O6                DrugBank          −8.971              −107.43            2                 Arg224                                                                   6.11       −6.24
  Compound 7        C29H30N6O4S1            Zinc              −8.743              −74.994            11                Leu396, Arg301                                                           4.57       −5.07
  Compound 8        C30H35N3O2              Zinc              −8.620              −74.959            46                Asp397                                                                   −0.05      −8.53
  Compound 9        C20H21N1O8P1            Druglikness       −8.609              −74.756            1                 Arg301, Asn235, Lys314                                                   1.16       −4.10
  Compound 10       C22H30N4O6              AntiHIV NCI       −8.530              −83.930            1                 Arg301, Asn235, Arg224, Glu238, Asn242                                   0.23       −4.76
  Compound 11       C21H24N2O5P1            Druglikness       −8.492              −63.345            2                 Lys314, Arg301, Arg373, Asn400                                           2.60       −4.06
  Compound 12       C22H19Cl3O5             Druglikness       −8.464              −67.858            5                 His380, Lys314                                                           4.31       −5.33
  Compound 13       C12H20N3O7              PUBCHEM           −8.386              −43.623            7                 Asn400, Asn242                                                           −2.00      −0.95
  Compound 14       C29H28F1N5O4S1          Druglikness       −8.301              −81.932            3                 Asp389, Leu396, His393, Asp397, Arg224                                   3.47       −5.73
  Compound 15       C41H32O11               Zinc              −8.281              −82.301            2                 Asn400, Val231                                                           4.80       −5.57
  Compound 16       C20H21N1O8P1            Schrodinger       −8.194              −68.208            9                 Arg301, Lys314, Asn235                                                   1.16       −4.10
  Compound 17       C33H32N4O8              Zinc              −8.098              −93.738            1                 Arg224, Arg373, Asn400                                                   3.61       −5.52
  Compound 18       C24H34N4O6              Druglikness       −8.089              −80.004            18                Asn235, Glu238, Asn242, Asp389, His393                                   0.53       −5.15
  Compound 19       C26H38N2O4              Druglikness       −8.050              −52.984            1                 Arg301                                                                   3.69       −5.55
  Compound 20       C23H19NO10              Druglikness       −8.036              −58.247            1                 Asn235, Arg301, Arg373, Asn400                                           3.27       −4.73

Compound2 (docking score −11.331) and compound3 (docking score −11.265) both have chrome-4-one group and trihydroxy methyl oxanyl moieties. In case of Compound2 the hydroxyl groups form strong H-bond interactions with Arg224 and Asp397 residues. The hydroxy groups of dihydroxyl phenyl moiety form strong interactions with Leu396 and His393. The Chrome-4-one moiety is oriented in such a way that it has hydrophobic interactions with Ala213, Leu394, and Met377.

In compound3 although it fitted well in the active site, however, the orientation was such that the hydroxy methoxy phenyl moiety did not have any H-bond interactions. Compound4 and compound14 are dicarboxamide derivatives. In Compound4, the dihydroxy propyl amino group had H-bonding interaction with Asn400 and Arg224 residues. Hydrophobic interactions were observed with Ala213, Val226, Ala234, Asn235, Leu394, Leu396, and Asp397 residues. In compound14, the carboxamide moiety interacted with Leu396 and His393 residues. The amino group attached to the thiazole ring had H-bond interaction with Arg224 and Asp397 residues. Compound5 (docking score −10.076) was structurally similar to Compound1. The phosphonate oxy groups formed strong H-bond interactions with side chain of Lys314 and Arg301 residues. The purine moiety formed H-bond with Ala213 residue and the carbamoyl moiety of pyridine had H-bonded interaction with Leu222 and Arg224 residues. Compound6 with docking score of −8.97 formed H-bond with Arg224 residue. It had strong hydrophobic interactions with Asp397, Leu396, Asn235, Ala234, Glu238, and Lys314 residues. Compound7 (docking score of −8.743) sits well in the cavity of GPR142. The indole triazine moiety has hydrophobic interactions with Phe212, Ala213, Ala234, Val226, Asp397, and Asn400 residues. The oxygen of imidazole ring forms H-bond with Leu396 residue. The oxygen of hexonoate group has strong H-bond with Arg301 residue. Compound8 well occupied the binding site of GPR142 through hydrophobic interactions. Only one H-bond was observed between aminogroup of benzylamino moiety and side chain of Asp397 residue. Compound9, compound11, and compound16 are derivatives of phosphonic acid. In all the three compounds, the phoshonic acid moiety formed H-bond with side chain of Arg301 and Lys314 residues. The oxygen of carbamoyl moiety formed H-bond with side chain of Asn235 in compound9, compound16 and Asn400 with compound11. Hydrophobic interactions were also observed with Val209, Val226, Ala234, Asn235, and Leu396. Compound10 and compound18 both have anthracene group. In compound10, hydroxyl ethyl amino group formed H-bond with Arg301, Asn235, Glu238, and Asn242 residues. Hydrophobic interactions were observed with Ala234 and Val226 residues; whereas, in compound18 the hydroxyl propyl amino group formed H-bond with His393 and Glu238 residues. The hydroxyl group attached to anthracene moiety showed H-bonding with Asn235 residue. Compound12 had mainly hydrophobic interactions and one hydrogen bond. The hydroxyl methyl group formed H-bond with Lys314 residue. Hydrophobic interactions were observed with Ala234, Asn235, and Glu238 residues. In compound13, hydroxyl group of pentahydroxy hexyl imino group formed H-bond with Asn242 and Asn400 residues. Hydrophobic interactions were observed with Ile206, Val209, Ala234, Arg224, and Ala213 residues. Compound15 had hydrophobic interactions with Phe212, Arg224, Ala234, Val231, Asn235, Leu396, His380, Asn400, and Asp397 residues. It did not show any strong H-bonds. Compound17 had strong H-bond interaction between with side chain of Arg224 and Arg373 residue. Hydrophobic interactions were observed with Asp397, Leu396, and His317 residues. In compound19, hydroxyl group of the phenyl moiety formed H-bond with side chain of Arg301 residue. The major hydrophobic interactions were with residues Ala213, Ala234, Asn235, Phe239, Lys314, Glu238, and Leu396. In compound20, hydroxyl group formed H-bonds with Asn235, Arg301, and Arg373 residues. Hydrophobic interactions were observed with Ala234, Glu238, and Leu396 residues.

Strong hydrogen bond interactions with amino acid residues Arg224, Asn235, Arg301, Lys314, Asn85, and Asp397 played a key role in binding affinity of potential compounds with GPR142. Therefore, compounds with donor or acceptor groups that can form H-bonds with these residues are likely to have better affinity.

Validation
----------

### Blind docking

In order to cross validate the above results blind docking for top compounds was performed. All the compounds docked in the active site region are shown in Figure [4](#F4){ref-type="fig"} and hence, eliminating the possibility of other binding sites for these screened compounds.

![Cross validation of active site region where top 20 compounds shown in different colors were docked at same active site regions which validate the structural activity.](fchem-06-00023-g0004){#F4}

### Induced fit docking

The most important feature of induced-fit docking (IFD) is that both ligand and the residues in receptor\'s active site and its vicinity are imparted flexibility. The results of IFD for the 10 screened compound was done to validate and refine the interactions (Table [3](#T3){ref-type="table"}). The Induced fit docking of compound2 with GPR142 (Figure [5](#F5){ref-type="fig"}) showed with best docking score of −13.449 and strong H-bonds. Therefore, compound2 was selected for further studies.

###### 

Top 10 potential screened chemical compounds after Induced Fit docking analysis showing the score and the non-bonded interactions.

  **Compound\'s**   **Induced fit (XP) docking**   **IFD score**   **XP interactions**
  ----------------- ------------------------------ --------------- --------------------------------------------------------------------------------
  Compound1         −11.173                        −577.105        Arg301, Trp300, Asp397, Asn235, Glu238, Lys314
  Compound2         −13.449                        −572.7          Arg224, Lys314, Leu396, His380, Asp397, His393, Asp389
  Compound3         −11.567                        −569.821        Asn235, Leu396, Asp397, Arg224, His380, Leu222, Asp389, His393
  Compound4         −9.6643                        −572.504        Ile206, Glu238, Arg373, Asn400, Arg224, Tyr322
  Compound5         −12.3708                       −574.37         Val383, Lys314, His380, Arg301, Asn235, Gln225, Leu222, Leu396, His393, Asp389
  Compound6         −10.468                        2828552         --
  Compound7         −9.1587                        969.8008        His380, Ala395, Leu396, Asp397
  Compound8         −10.600                        −575.545        Glu238
  Compound9         −9.7384                        −572.791        Lys314, Arg301, Asn235
  Compound10        −10.170                        −565.303        Trp370, Arg373, Asn400, Asp397, His393, Asp389

![Compound2 with the highest Induced Fit docking score after docking at same active site, where receptor and ligand both were flexible. Interacting residues are shown as sticks. The dotted lines respresent the H-bonded interactions.](fchem-06-00023-g0005){#F5}

### Common pharmacophore hypotheses generation

A common pharmacophore hypothesis was generated using Phase module of Schrodinger suite software. The known experimental EC~50~ values for chemical compounds was retrieved from the literature. For information of experimental compounds used in study see Supplementary Data (Table [S1](#SM1){ref-type="supplementary-material"}). Using selected variants, the common pharmacophore hypothesis was generated amongst the given active ligands (Table [4](#T4){ref-type="table"}). For scoring, the maximum and minimum number of sites were set at 7 and 4, respectively with a threshold such that at least 30 compounds should match out of 51 actives. Clustering was done to score hypotheses, vector and site filtering to retain those with RMSD below 1.20 Å and vector score above 0.50 Å. The best score hypotheses was ADPRR (Figure [6](#F6){ref-type="fig"}) with 3.224 survival score, 0.71 site score, 0.912 vector score, 0.604 volume of pharmacophoric feature. Survival score was calculated using survival score formula (1.000 vector score, plus 1.000 site score, plus 1.000 volume score, minus 0.000 reference ligand relative conformational energy, plus 0.000 selective score, plus 1.000 number of matches, plus 0.000 reference ligand activity).

###### 

Selected variants for common pharmacophore hypothesis.

  **Variant**   **Maximum number of hypotheses**
  ------------- ----------------------------------
  ADRRR         1
  AADPR         5
  AAPRR         8
  APRRR         7
  DPRRR         6
  ADPRR         22
  AADRR         3

![Representation of common pharmacophore hypotheses, where R5 has most important common pharmacophoric feature required to inhibit Type 2 diabetes.](fchem-06-00023-g0006){#F6}

### Pharmacophore matching in screened compounds

Further, to investigate whether some of the screened compounds shared the pharmacophoric features derived from known potential GPR142 agonists, 1038 compounds obtained through receptor based virtual screening were searched for matches with pharmacophore hypothesis. Some of the screened compounds shared the same pharmacophoric features. Top 10 compounds showed ADPRR pharmacophoric features and their 2D structure are given in Supplementary Data (Table [S2](#SM1){ref-type="supplementary-material"}); where compound21 showed good binding affinity with the docking score of −6.470. Interestingly, Compound21-Compound 30 had good docking scores; however, comparatively the experimental compound (compoundE1) had better docking scores and stronger interactions. Comparative analysis between one of the compounds (CompoundE1) with EC~50~ 0.036 and compound21 revealed that both the compounds bound to the active site of GPR142. CompoundE1 had a docking score of −4.860 against that of −6.470 for compound21. Also, in CompoundE1 (mol wt: 450.56 g/mol) the amino group attached to the thiazole moiety formed H-bond with Glu238. It had hydrophobic interactions with Val204, Asn235, Ala234, Leu396, Asp397, where molecular weight of experimental compound was 450.568 g/mol shown in (Figure [7A](#F7){ref-type="fig"}). Compound21 (mol. Wt: 442.51 g/mol) had two strong H-bonded interactions with Arg224 and Leu396 residues. Hydrophobic interactions formed with Ala213, Val231, Ala234, Lys314, Met377, Leu394, Asp397, and His393 residues (Figure [7B](#F7){ref-type="fig"}). Using Pharmacophoric hypotheses approach new potential lead compounds were identified. ADMET analysis of compoundE1 showed logP value of 2.54 and logs value of −4.67 while compound21 showed good bioavailability of the compounds with oral absorption value of 93.391%, logP value 3.00 and logS value −5.88.

![**(A)** Represents the docked complex of GPR142 with CompoundE1 (Experimental compound) and **(B)** Represents the docking complex of GPR142 with compound21. Hydrogen bonded interactions are shown as dotted lines. For clarity, only few transmembrane domains of the protein are shown.](fchem-06-00023-g0007){#F7}

### Biochemical pathway of GPR142 complexes with screened compound

The biochemical pathway of GPR142 complexes with compound2 and compound21 was constructed to study the effects of these compounds under the assumption that these compounds bind to GPR142, as shown by virtual screening, on the biochemical pathway in type 2 diabetes. In the network three different signaling pathways were identified through which insulin secretion enhanced on binding of compound2 and compound21 with GPR142 (Figure [8](#F8){ref-type="fig"}). Stimulation of GPR142 by diverse hormones, growth factors and compounds stimulate the hydrolysis of Phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C (PLC) and produces two second messenger as diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) through activation of Gq signaling pathway. (1) DAG in turn stimulates protein kinase C (PKC) which triggers insulin secretion. These results agree with the experimental results that activation of Gq and Gi signaling by GPR142 agonists can stimulate glucose-dependent insulin secretion. (2) IP3 stimulates downstream signaling pathways and activates Ca^2+^ mobilization which may enhance insulin secretion. (3) GPR142 through Gi signaling pathway binds to adenyl cyclase (AC) and activates cAMP pathway which may regulate insulin secretion through protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). The kinetic simulations of the test compounds were done at different concentrations to see the effect on insulin production. The kinetic studies were carried out using different concentration of compounds. The optimum concentration which enhanced the insulin production was taken as 0.036 μM for compound2 (Figure [9](#F9){ref-type="fig"}). We previously published complete biochemical pathway of GPR142 network involved in type 2 diabetes (Kaushik and Sahi, [@B51]). The results showed significant increase in insulin production. However, an inhibitory effect was observed on cAMP production. This could be due to activation of GPR142 through Gq signaling pathway via DAG and IP3. The effect of different compounds/substrates/messengers on insulin and glucagon secretion is given in (Table [5](#T5){ref-type="table"}) (Winzell and Ahrén, [@B72]).

![Network depicting three different signaling pathways through which insulin secretion may be enhanced on binding of compound2 and compound21 with GPR142.](fchem-06-00023-g0008){#F8}

![Kinetic studies of compound2 and its effect on insulin secretion X-axis represent the concentration of species and Y-axis represents the time of interaction.](fchem-06-00023-g0009){#F9}

###### 

Hormones, ATP/ADP, ions and nutrients that affect insulin secretion via interaction through GPC.

  **Ligand**   **Receptor**   **Effect on insulin secretion**   **Effect on glucagon secretion**   **G protein**   **Concentrations (mumol)**           
  ------------ -------------- --------------------------------- ---------------------------------- --------------- ---------------------------- ------- -------
  ATP/ADP      P~2*Y*~        Stimulatory                       Not known                          G~s~            1                            0.1     1.9
  CCK          CCK~*A*~       Stimulatory                       Stimulatory                        G~q~            1                            0.1     1.9
  Compound2    GPR142         Stimulatory                       Not known                          G~s~            0.036                        0.036   0.068
  Compound21   GPR142         Stimulatory                       Not known                          G~s~            0.036                        0.036   0.068
  Glucagon     Gcgr           Stimulatory                       Stimulatory                        G~s~, G~q~      1                            0.1     1.9
  GLP-1        GLP-1R         Stimulatory                       Inhibitory                         G~s~            1                            0.1     1.9
  GIP          GIPR           Stimulatory                       Stimulatory                        G~s~            1                            0.1     1.9
  NPY          Y~1~           Inhibitory                        Stimulatory                        G~i~            1                            0.1     1.9
  PACAP        PAC~1~         Stimulatory                       Stimulatory                        G~s~            1                            0.1     1.9
  Ach          Ca^2+^/K^+^    Stimulatory                       Stimulatory                        G~q~            1                            0.1     1.9
  AC           cAMP           Stimulatory                       No Effect/ Modulating              G~i/o~          1                            0.1     1.9
  PLC          IP3/PIP2/DAG   Stimulatory                       Inhibitory                         G~i~            1                            0.1     1.9
  PKA          GPCR           Modulating Secretion              Inhibitory                         G~q~            1                            0.1     1.9
  cAMP         Epac           Inhibitory                        Stimulatory                        G~i~            1                            0.1     1.9
  DAG analog   PKC            Stimulatory                       Inhibitory                         G~i~            1                            0.1     1.9

### Molecular dynamics simulation

Molecular dynamics (MD) simulations provided an insight into dynamic perturbations within the complex and interactions of ligand, lipid and water molecules.

The root mean square deviations (RMSD) of complex2 and complex21 protein were analyzed using carbon alpha (Cα) atoms and stability of compounds by using heavy atoms RMSD over 50 ns on generated 10430 trajectory frames. The complex2 protein Cα atoms RMSD showed between 1.8 and 2.7 Å while in complex21 showed higher RMSD but in constant range between 2.4 and 2.8 Å which is also comes in stable and acceptable range (Figures [10A,B](#F10){ref-type="fig"}). Compund2 heavy atoms showed stable and constant RMSD between 1.2 and 1.8 Å. It also showed some fluctuations in RMSD between 20 and 25 ns, after 25 ns it remain constant till end of the simulation. Compound21 also showed constant RMSD at 0.8 Å that means it was stable throughout simulation time.

![**(A)** RMSD of carbon alpha atoms of complex structure of compound2 for 50 ns simulation, where Y axis represents the RMSD value in Å and X axis represents the Time (ns) for GPR142 structure and compound21. **(B)** RMSD of carbon alpha atoms of complex structure of compound21 for 50 ns simulation, where Y axis represents the RMSD value in Å and X axis represents the Time (ns) of GPR142 structure and compound21. **(A1)** RMSF of carbon alpha of complex structure of compound2 for 50 ns simulation, where Y axis represents the RMSF value and X axis represents residues, where blue peaks represents the backbone, green peaks represents the ligand contacts. **(B1)** RMSF of carbon alpha of complex structure of compound21 for 50 ns simulation, where Y axis represents the RMSF value and X axis represents residues, where blue peaks represents the backbone, green peaks represents the ligand contacts.](fchem-06-00023-g0010){#F10}

The fluctuations in local domain of protein Cα atoms and effect of compounds binding in protein analyzed by root mean square fluctuations plot. Complex2 and 21 showed two higher fluctuations in loop regions, first fluctuation in loop which connects domain 3 and 4 between 300 and 312 residues and second connects domain 5 and 6 between 345 and 356 residues. N-terminal has large loop region between 421 and 450 residues with fluctuations in the acceptable range between 1.8 and 2.8 Å for the both complexes. Domain 3 and 4 loops did not show binding with compound2 while binding was recorded in compound21 (Figures [10A1,B1](#F10){ref-type="fig"}).

The interaction fraction analysis of ligand binding mode in protein based on occupancy of hydrogen and hydrophobic bonding throughout simulation periods. Compound2 showed more than 90% hydrogen boding with Asn235 and Glu238 while 20% with Arg224, His393, Asp397, and Asn400 residues. Hydrophobic occupancy showed between 30 and 60% during simulation with Val209, Phe212, Ala213, Val226, Met377, His380, Met381, Pro385, and Leu396 residues. In compound21, showed less than 20% hydrogen bonding with Arg224 and Leu396 while showed hydrophobic occupancy between 20 and 50% with the Val209, Ile210, Phe239, Lys314, Tyr322, Arg373, Met377, His380, Pro235 residues. These interaction fractions suggested that compound2 had strong binding affinity in comparison to compare compound21 as given in Supplementary Data (Figure [S1](#SM1){ref-type="supplementary-material"}).

Conclusions {#s4}
===========

GPR142 is a potential drug target for diabetes. Using structure based virtual screening at the active site of GPR142, 1038 compounds were screened as potential inhibitors from the set of 1171519 compounds at different libraries. Further, top twenty screened compounds were selected and validated by blind docking and induced fit docking studies. The compounds that showed strong hydrogen bond interactions with amino acid residues Arg224, Asn235, Arg301, Lys314, and Asp397 were concluded as potential agonists of GPR142. Also, a pharmacophore hypothesis was generated using compounds with known EC50 values that searched against the screened compounds. A few compounds amongst the screened compounds shared the same pharmacophoric features as observed in the compounds reported in literature. The system biology approach was used to study the effect of compound2 and compound21 on insulin secretion. Interestingly both the compounds triggered insulin secretion on binding to GPR142 via Gq signaling pathway. Thus, we were able to identify structurally diverse compounds particularly compound1, compound2 and compound21 which can be used as scaffold to design and develop lead GPR142 agonists.
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